Polymyositis, dermatomyositis and inclusion body myositis

Idiopathic inflammatory myopathy is a group of diseases of unknown aetiology and probably autoimmune pathogenesis (Tables I, II). Treatment of the diseases is divided into the following stages: initial phase, intermediate phase, and long-lasting therapy. Glucocorticoids and other immunosuppressive drugs (commonly azathioprine and methotrexate) are applied for management. It is important to evaluate activity of the disease, effectiveness of the treatment and occurrence of adverse reactions. Inclusion body myositis is resistant to glucocorticoid therapy.

REFERENCES (6)

Lundberg IE, Vencovsky J, Dani L. Polymyositis, dermatomyositis, inflammatory diseases of muscles and other myopathies. In: EULAR Compendium. Bijlsma JW, et al. (eds.). BMJ, London 2009: 297-313.

Google Scholar

Kucharz EJ. Idiopatyczna miopatia zapalna. W: Reumatologia. Wielka interna. Puszczewicz M (red.). Medical Tribune Polska, Warszawa 2010; 148-156.

Google Scholar

Hengstma GJ, van den Hoogen FH, van Engelen BG. Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother 2009; 10: 1183-1190.

Google Scholar

Chwalińska-Sadowska H, Małdykowa H. Polymyositis – dermatomyositis: 25 years of follow-up of 50 patients disease course, treatment, prognostic factors. Mater Med Pol 1990; 22: 213-218.

Google Scholar

Kucharz EJ. Zapalenie mięśni z ciałkami wtrętowymi. Pol Arch Med Wewn 1998; 100: 262-266.

Google Scholar

Kucharz EJ. Dziedziczna miopatia z ciałkami wtrętowymi. Przegl Lek 1999; 56: 735-738.

Google Scholar

Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Submit your paper

eISSN:	2084-9834
ISSN:	0034-6233